NEW YORK (GenomeWeb News) – Eureka Genomics plans to merge with Nanobac Pharmaceuticals under a stock and cash deal, the bioinformatics company said today.

Under a memorandum of understanding, Eureka stockholders will receive new shares of Nanobac common stock and own 85 percent of the combined company, which will operate under the Eureka Genomics name. Nanobac has already provided Eureka with initial funds, and the deal is expected to close in the second quarter of 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.